What NMR can do in the biopharmaceutical industry

•Biosimilars development.•The multiple role of modern NMR spectroscopy.•Characterizing therapeutic proteins. Nuclear magnetic resonance (NMR) spectroscopy has a unique capability to probe the primary and higher order molecular structure and the structural dynamics of biomolecules at an atomic resolu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical and biomedical analysis 2018-01, Vol.147, p.367-377
Hauptverfasser: Kiss, Róbert, Fizil, Ádám, Szántay, Csaba
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 377
container_issue
container_start_page 367
container_title Journal of pharmaceutical and biomedical analysis
container_volume 147
creator Kiss, Róbert
Fizil, Ádám
Szántay, Csaba
description •Biosimilars development.•The multiple role of modern NMR spectroscopy.•Characterizing therapeutic proteins. Nuclear magnetic resonance (NMR) spectroscopy has a unique capability to probe the primary and higher order molecular structure and the structural dynamics of biomolecules at an atomic resolution, and this capability has been greatly fortified over the last five decades by an astonishing NMR instrumental and methodological development. Because of these factors, NMR has become a primary tool for the structure investigation of biomolecules, spawning a whole scientific subfield dedicated to the subject. This role of NMR is by now well established and broadly appreciated, especially in the context of academic research dealing with proteins that are purified and isotope-labeled in order to facilitate the necessary sophisticated multidimensional NMR measurements. However, the more recent industrial development, manufacturing, and quality control of biopharmaceuticals provide a different framework for NMR. For example, protein drug substances are not isotope-labeled and are present in a medium of excipients, which make structural NMR measurements much more difficult. On the other hand, biotechnology involves many other analytical requirements that can be efficiently addressed by NMR. In this respect the scope and limitations of NMR are less well understood. Having the non-expert reader in mind, herein we wish to highlight the ways in which modern NMR can effectively support biotechnological developments. Our focus will be on biosimilar proteins, pointing out certain cases where its use is probably essential. Based partly on literature data, and partly on our own hands-on experience, this paper is intended to be a guide for choosing the proper NMR approach for analytical questions concerning the structural comparability of therapeutic proteins, monitoring technology-related impurities, protein quantification, analysis of spent media, identification of extractable and leachable components, etc. Also, we focus on critical considerations, particularly those coming from drug authority guidelines, which limit the use of the well-established NMR tools in everyday practice.
doi_str_mv 10.1016/j.jpba.2017.07.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1925273179</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708517313572</els_id><sourcerecordid>1925273179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-90d9eb97aac100e3c212ddc4a8a702079f7bf66d029c0c422e7415389511b823</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozjj6B1xIl25ab9K0acCNDL5gVJAB3YU0SZmUvkxaYf69GWZ0KRy4i_udA-cgdIkhwYDzmzqph1ImBDBLIAjoEZrjgqUxyennMZoDS3HMoMhm6Mz7GgAyzOkpmpGC5ZAymCP8sZFj9PryHinZRbqPbBeNGxOVth820rVSmWm0SjbhoSc_uu05Oqlk483F4S7Q-uF-vXyKV2-Pz8u7Vaxono8xB81NyZmUCgOYVBFMtFZUFpIBAcYrVlZ5roFwBYoSYhjFWVrwDOOyIOkCXe9jB9d_TcaPorVemaaRneknLzAnGQn9GA8o2aPK9d47U4nB2Va6rcAgdkuJWuyWErulBAQBDaarQ_5Utkb_WX6nCcDtHjCh5Lc1TnhlTaeMts6oUeje_pf_A_KSd8Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1925273179</pqid></control><display><type>article</type><title>What NMR can do in the biopharmaceutical industry</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kiss, Róbert ; Fizil, Ádám ; Szántay, Csaba</creator><creatorcontrib>Kiss, Róbert ; Fizil, Ádám ; Szántay, Csaba</creatorcontrib><description>•Biosimilars development.•The multiple role of modern NMR spectroscopy.•Characterizing therapeutic proteins. Nuclear magnetic resonance (NMR) spectroscopy has a unique capability to probe the primary and higher order molecular structure and the structural dynamics of biomolecules at an atomic resolution, and this capability has been greatly fortified over the last five decades by an astonishing NMR instrumental and methodological development. Because of these factors, NMR has become a primary tool for the structure investigation of biomolecules, spawning a whole scientific subfield dedicated to the subject. This role of NMR is by now well established and broadly appreciated, especially in the context of academic research dealing with proteins that are purified and isotope-labeled in order to facilitate the necessary sophisticated multidimensional NMR measurements. However, the more recent industrial development, manufacturing, and quality control of biopharmaceuticals provide a different framework for NMR. For example, protein drug substances are not isotope-labeled and are present in a medium of excipients, which make structural NMR measurements much more difficult. On the other hand, biotechnology involves many other analytical requirements that can be efficiently addressed by NMR. In this respect the scope and limitations of NMR are less well understood. Having the non-expert reader in mind, herein we wish to highlight the ways in which modern NMR can effectively support biotechnological developments. Our focus will be on biosimilar proteins, pointing out certain cases where its use is probably essential. Based partly on literature data, and partly on our own hands-on experience, this paper is intended to be a guide for choosing the proper NMR approach for analytical questions concerning the structural comparability of therapeutic proteins, monitoring technology-related impurities, protein quantification, analysis of spent media, identification of extractable and leachable components, etc. Also, we focus on critical considerations, particularly those coming from drug authority guidelines, which limit the use of the well-established NMR tools in everyday practice.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2017.07.004</identifier><identifier>PMID: 28760370</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Animals ; Bioanalytics ; Biopharmaceutics ; Biopharmaceutics - methods ; Biosimilar Pharmaceuticals - analysis ; Biosimilar Pharmaceuticals - chemistry ; Biosimilarity ; Drug Industry - methods ; Higher order structure ; Humans ; NMR ; Nuclear Magnetic Resonance, Biomolecular - methods ; Therapeutic proteins</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2018-01, Vol.147, p.367-377</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-90d9eb97aac100e3c212ddc4a8a702079f7bf66d029c0c422e7415389511b823</citedby><cites>FETCH-LOGICAL-c466t-90d9eb97aac100e3c212ddc4a8a702079f7bf66d029c0c422e7415389511b823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0731708517313572$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28760370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kiss, Róbert</creatorcontrib><creatorcontrib>Fizil, Ádám</creatorcontrib><creatorcontrib>Szántay, Csaba</creatorcontrib><title>What NMR can do in the biopharmaceutical industry</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>•Biosimilars development.•The multiple role of modern NMR spectroscopy.•Characterizing therapeutic proteins. Nuclear magnetic resonance (NMR) spectroscopy has a unique capability to probe the primary and higher order molecular structure and the structural dynamics of biomolecules at an atomic resolution, and this capability has been greatly fortified over the last five decades by an astonishing NMR instrumental and methodological development. Because of these factors, NMR has become a primary tool for the structure investigation of biomolecules, spawning a whole scientific subfield dedicated to the subject. This role of NMR is by now well established and broadly appreciated, especially in the context of academic research dealing with proteins that are purified and isotope-labeled in order to facilitate the necessary sophisticated multidimensional NMR measurements. However, the more recent industrial development, manufacturing, and quality control of biopharmaceuticals provide a different framework for NMR. For example, protein drug substances are not isotope-labeled and are present in a medium of excipients, which make structural NMR measurements much more difficult. On the other hand, biotechnology involves many other analytical requirements that can be efficiently addressed by NMR. In this respect the scope and limitations of NMR are less well understood. Having the non-expert reader in mind, herein we wish to highlight the ways in which modern NMR can effectively support biotechnological developments. Our focus will be on biosimilar proteins, pointing out certain cases where its use is probably essential. Based partly on literature data, and partly on our own hands-on experience, this paper is intended to be a guide for choosing the proper NMR approach for analytical questions concerning the structural comparability of therapeutic proteins, monitoring technology-related impurities, protein quantification, analysis of spent media, identification of extractable and leachable components, etc. Also, we focus on critical considerations, particularly those coming from drug authority guidelines, which limit the use of the well-established NMR tools in everyday practice.</description><subject>Animals</subject><subject>Bioanalytics</subject><subject>Biopharmaceutics</subject><subject>Biopharmaceutics - methods</subject><subject>Biosimilar Pharmaceuticals - analysis</subject><subject>Biosimilar Pharmaceuticals - chemistry</subject><subject>Biosimilarity</subject><subject>Drug Industry - methods</subject><subject>Higher order structure</subject><subject>Humans</subject><subject>NMR</subject><subject>Nuclear Magnetic Resonance, Biomolecular - methods</subject><subject>Therapeutic proteins</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAUhYMozjj6B1xIl25ab9K0acCNDL5gVJAB3YU0SZmUvkxaYf69GWZ0KRy4i_udA-cgdIkhwYDzmzqph1ImBDBLIAjoEZrjgqUxyennMZoDS3HMoMhm6Mz7GgAyzOkpmpGC5ZAymCP8sZFj9PryHinZRbqPbBeNGxOVth820rVSmWm0SjbhoSc_uu05Oqlk483F4S7Q-uF-vXyKV2-Pz8u7Vaxono8xB81NyZmUCgOYVBFMtFZUFpIBAcYrVlZ5roFwBYoSYhjFWVrwDOOyIOkCXe9jB9d_TcaPorVemaaRneknLzAnGQn9GA8o2aPK9d47U4nB2Va6rcAgdkuJWuyWErulBAQBDaarQ_5Utkb_WX6nCcDtHjCh5Lc1TnhlTaeMts6oUeje_pf_A_KSd8Y</recordid><startdate>20180105</startdate><enddate>20180105</enddate><creator>Kiss, Róbert</creator><creator>Fizil, Ádám</creator><creator>Szántay, Csaba</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180105</creationdate><title>What NMR can do in the biopharmaceutical industry</title><author>Kiss, Róbert ; Fizil, Ádám ; Szántay, Csaba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-90d9eb97aac100e3c212ddc4a8a702079f7bf66d029c0c422e7415389511b823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Bioanalytics</topic><topic>Biopharmaceutics</topic><topic>Biopharmaceutics - methods</topic><topic>Biosimilar Pharmaceuticals - analysis</topic><topic>Biosimilar Pharmaceuticals - chemistry</topic><topic>Biosimilarity</topic><topic>Drug Industry - methods</topic><topic>Higher order structure</topic><topic>Humans</topic><topic>NMR</topic><topic>Nuclear Magnetic Resonance, Biomolecular - methods</topic><topic>Therapeutic proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kiss, Róbert</creatorcontrib><creatorcontrib>Fizil, Ádám</creatorcontrib><creatorcontrib>Szántay, Csaba</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kiss, Róbert</au><au>Fizil, Ádám</au><au>Szántay, Csaba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What NMR can do in the biopharmaceutical industry</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2018-01-05</date><risdate>2018</risdate><volume>147</volume><spage>367</spage><epage>377</epage><pages>367-377</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><abstract>•Biosimilars development.•The multiple role of modern NMR spectroscopy.•Characterizing therapeutic proteins. Nuclear magnetic resonance (NMR) spectroscopy has a unique capability to probe the primary and higher order molecular structure and the structural dynamics of biomolecules at an atomic resolution, and this capability has been greatly fortified over the last five decades by an astonishing NMR instrumental and methodological development. Because of these factors, NMR has become a primary tool for the structure investigation of biomolecules, spawning a whole scientific subfield dedicated to the subject. This role of NMR is by now well established and broadly appreciated, especially in the context of academic research dealing with proteins that are purified and isotope-labeled in order to facilitate the necessary sophisticated multidimensional NMR measurements. However, the more recent industrial development, manufacturing, and quality control of biopharmaceuticals provide a different framework for NMR. For example, protein drug substances are not isotope-labeled and are present in a medium of excipients, which make structural NMR measurements much more difficult. On the other hand, biotechnology involves many other analytical requirements that can be efficiently addressed by NMR. In this respect the scope and limitations of NMR are less well understood. Having the non-expert reader in mind, herein we wish to highlight the ways in which modern NMR can effectively support biotechnological developments. Our focus will be on biosimilar proteins, pointing out certain cases where its use is probably essential. Based partly on literature data, and partly on our own hands-on experience, this paper is intended to be a guide for choosing the proper NMR approach for analytical questions concerning the structural comparability of therapeutic proteins, monitoring technology-related impurities, protein quantification, analysis of spent media, identification of extractable and leachable components, etc. Also, we focus on critical considerations, particularly those coming from drug authority guidelines, which limit the use of the well-established NMR tools in everyday practice.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>28760370</pmid><doi>10.1016/j.jpba.2017.07.004</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0731-7085
ispartof Journal of pharmaceutical and biomedical analysis, 2018-01, Vol.147, p.367-377
issn 0731-7085
1873-264X
language eng
recordid cdi_proquest_miscellaneous_1925273179
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Bioanalytics
Biopharmaceutics
Biopharmaceutics - methods
Biosimilar Pharmaceuticals - analysis
Biosimilar Pharmaceuticals - chemistry
Biosimilarity
Drug Industry - methods
Higher order structure
Humans
NMR
Nuclear Magnetic Resonance, Biomolecular - methods
Therapeutic proteins
title What NMR can do in the biopharmaceutical industry
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A36%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20NMR%20can%20do%20in%20the%20biopharmaceutical%20industry&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Kiss,%20R%C3%B3bert&rft.date=2018-01-05&rft.volume=147&rft.spage=367&rft.epage=377&rft.pages=367-377&rft.issn=0731-7085&rft.eissn=1873-264X&rft_id=info:doi/10.1016/j.jpba.2017.07.004&rft_dat=%3Cproquest_cross%3E1925273179%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1925273179&rft_id=info:pmid/28760370&rft_els_id=S0731708517313572&rfr_iscdi=true